IGF-1 LR3
Long R3 IGF-1
Long-acting IGF-1 analog. High-risk research compound.
An IGF-1 analog with an N-terminal extension and Arg3 substitution that reduces IGFBP binding and extends half-life. Potent anabolic signal with a meaningful hypoglycemia and theoretical cancer-risk profile.
Usual range
20–80 mcg
Schedule
Once daily, short cycle
Half-life
~20–30 hours (LR3)
How it is used
Long-acting IGF-1 analog. High-risk research compound.
Subcutaneous · also Intramuscular
Post-training with carbs available. Have fast carbs on hand for hypoglycemia.
4 weeks maximum is a common ceiling. Not a lifestyle peptide.
How to mix this vial
Typical vial 1 mg · 1 mL BAC
Often reconstituted in 0.6% acetic acid, not BAC. 1 mg + 1 mL → 1000 mcg/mL. 20 mcg = 2 units. Handle as high-risk.
Freezer for lyophilized long-term; fridge once mixed. Do not freeze reconstituted.
Side effects
- Hypoglycemia
- Injection-site lumps
- Jaw/hand ache
- Theoretical tumor promotion
Who should skip this
- Any cancer history
- Diabetes without specialist care
- Pregnancy
- Adolescence
Nutrition note
Carbohydrate available around the dose. Never inject fasted. Protein 2 g/kg.
Among the highest-risk entries in this library. Not comparable to GHRH/GHRP pulses.
Peptipedia is an educational calculator, not medical advice. Many catalog entries are unapproved for human use. Approved molecules have labels that outrank this app. Do not use this to self-prescribe. Consult a licensed clinician. Not for anyone under 18, pregnant, or being treated for cancer.